|Dr. John A. Scarlett||CEO, Pres & Chairman||1.15M||N/A||1951|
|Ms. Olivia Kyusuk Bloom||Exec. VP of Fin., CFO & Treasurer||687.17k||N/A||1969|
|Dr. Andrew J. Grethlein||Exec. VP & COO||705.69k||N/A||1964|
|Ms. Melissa A. Kelly Behrs||Exec. VP & Chief Bus. Officer||673.36k||N/A||1964|
|Dr. Aleksandra Rizo M.D., Ph.D.||Exec. VP & Chief Medical Officer||968.2k||N/A||1975|
|Ms. Suzanne Messere||Head of Investor Relations & Corp. Communications||N/A||N/A||N/A|
|Mr. Stephen N. Rosenfield||Exec. VP, Chief Legal Officer & Corp. Sec.||N/A||N/A||1950|
|Ms. Shannon Odam||VP of HR||N/A||N/A||N/A|
|Mr. Anil Kapur||Chief Commercial Officer & Exec. VP of Corp. Strategy||N/A||N/A||1970|
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for hematologic myeloid malignancies. It holds rights to imetelstat, a telomerase inhibitor in Phase 2/3 clinical trials, which inhibits the uncontrolled proliferation of malignant progenitor cells in hematologic myeloid malignancies to reduce dysfunctional blood cell production and enable recovery of normal blood cell production. The company was founded in 1990 and is headquartered in Menlo Park, California.
Geron Corporation’s ISS governance QualityScore as of 1 December 2020 is 6. The pillar scores are Audit: 1; Board: 2; Shareholder rights: 8; Compensation: 8.